New antiretrovirals and new combinations

Area of Science:

• Pharmacology and Infectious Diseases
• Antiretroviral Therapy Development

Background:

• Annual introduction of new antiretroviral agents since 1995 has revolutionized HIV treatment.
• International collaborative efforts drive rapid and safe development of novel HIV therapies.
• Clinicians face challenges in integrating new drug data into patient management strategies.

Purpose of the Study:

• To review the clinical profiles of recently approved and late-stage antiretroviral drugs.
• To summarize new data on combination antiretroviral therapy regimens.
• To highlight the importance of clinical studies for characterizing combination therapy safety and efficacy.

Main Methods:

• Review of clinical profiles for new drugs like nelfinavir, nevirapine, delavirdine, DMP-266, abacavir, and 141W94.
• Summarization of recent clinical data on nucleoside, protease inhibitor, and non-nucleoside reverse transcriptase inhibitor combinations.
• Brief mention of antiretroviral agents in early developmental stages.

Main Results:

• Combination therapy, such as indinavir, lamivudine, and zidovudine, achieves profound and sustained viral suppression.
• Previously contraindicated combinations, like didanosine and stavudine, show good tolerability and efficacy.
• Potential for pharmacologic antagonism and unexpected toxicities exists with certain drug combinations.

Conclusions:

• Combination antiretroviral therapy is the most effective approach for managing HIV disease.
• Carefully conducted clinical studies are crucial for understanding the safety, pharmacokinetics, and efficacy of new combination regimens.
• Further research is needed to explore the full potential of existing and novel antiretroviral drug combinations.